AVTX 8-K 2026-11-05

Avalo Therapeutics, Inc. (AVTX) 8-K dated 2026-11-05 — accession 0001104659-26-123079.

Avalo Therapeutics, Inc. (AVTX) is a biotechnology company listed on US.

Avalo Therapeutics, Inc. filed a 8-K on 2026-11-05. Accession 0001104659-26-123079.

This 8-K covers: Material agreement (Item 1.01), Agreement ended (Item 1.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported AVTX revenue for 2025-12-31 was $59.0K. Net income was -$78.3M. Revenue was down 86.6% from 2024-12-31 to 2025-12-31. AVTX currently screens at market cap $51.5M.

Not investment advice. The AVTX SEC hub lists recent forms. The stock page is the research view.